RamezNassefEskanderMD

PubMed

• Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.
  Nishizaki, D., Eskander, R.> ;Surgical Oncology Clinics of North America. 2024 Apr 1
• Recent Therapeutic Advances in Gynecologic Oncology: A Review.
  Wilson, E., Eskander, R., Binder, P.> ;Cancers. 2024 Feb 13
• Revisiting immunotherapy in endometrial cancer.
  Eskander, R.> ;Clinical Advances in Hematology & Oncology. 2024 Jan 31
• Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy.
  Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K Nesline, Jeffrey M Conroy, Eitan Rubin, Ramez N Eskande...> ;Molecular Cancer Therapeutics. 2023 Nov 1
• 1 citations
  Prevention of venous thromboembolism in patients with cancer.
  Saketh R Guntupalli, Daniel Spinosa, Stephanie Wethington, Ramez Eskander, Alok A Khorana> ;BMJ. 2023 Jun 1
• 11 citations
  Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
  Debra L Richardson, Ramez N Eskander, David M O'Malley> ;JAMA Oncology. 2023 Jun 1
• 80 citations
  Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
  Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa, Robert Mannel, Mark S Shahin, Guilherme H Cantuaria, Eugenia Girda, C...> ;The New England Journal of Medicine. 2023 Jun 8
• Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy.
  Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary Nesline, Jeffrey Conroy, Eitan Rubin, Ramez Eskander, Raz...> ;Research Square. 2023 Feb 16
• 7 citations
  Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inh...
  Ryon P Graf, Kunal Shah, Natalie Danziger, Douglas I Lin, Julia Quintanilha, Gerald Li, James Haberberger, Jeffrey S Ross, Alessandro D Santin, Brian Slomovitz, Julia ...> ;International Journal of Gynecological Cancer. 2023 Apr 3
• 1 citations
  Immunotherapy treatment landscape for patients with endometrial cancer: current evidence and future opportunities.
  Marianne Hom-Tedla, Ramez N Eskander> ;Clinical Advances in Hematology & Oncology. 2023 Jan 1
• 3 citations
  Overcoming the challenges of drug development in platinum-resistant ovarian cancer.
  Ramez N Eskander, Kathleen N Moore, Bradley J Monk, Thomas J Herzog, Christina M Annunziata, David M O'Malley, Robert L Coleman> ;Frontiers in Oncology. 2023 Jan 1
• 5 citations
  Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy.
  Bryan H Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N Eskander, Gregory Botta, Hitendra Patel, Suzanna Lee, Scott M Lippman, Jason K Sicklic...> ;NPJ Precision Oncology. 2022 Sep 22
• 1 citations
  Immunotherapy toxicities: An SGO clinical practice statement.
  R E O'Cearbhaill, L Clark, R N Eskander, S Gaillard, J Moroney, E Pereira, B Pothuri> ;Gynecologic Oncology. 2022 Jul 1
• 2 citations
  Practice changing cervical cancer clinical trials.
  Bhavana Pothuri, Ramez N Eskander, Leslie M Randall, David M O'Malley, Brian Slomovitz, Kathleen N Moore, Thomas J Herzog, Robert L Coleman, Larry J Copeland, Bradley ...> ;Gynecologic Oncology. 2022 Jun 1
• 37 citations
  Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test.
  Juan Pablo Hinestrosa, Razelle Kurzrock, Jean M Lewis, Nicholas J Schork, Gregor Schroeder, Ashish M Kamat, Andrew M Lowy, Ramez N Eskander, Orlando Perrera, David Sea...> ;Communications Medicine. 2022 Jan 1
• 7 citations
  Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
  Lindsey M Charo, Ramez N Eskander, Jason Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Suzanna Lee, Rupa Subramanian, Richard Schwab, Rebecca Shatsky, Steven ...> ;JCO Precision Oncology. 2022 Jan 1
• 11 citations
  Improved Prognosis of Treatment Failure in Cervical Cancer with Non-Tumor Positron Emission Tomography / Computed Tomography Radiomics.
  Tahir Yusufaly, Jingjing Zou, Tyler J. Nelson, Casey W. Williamson, Aaron B. Simon, Meenakshi Singhal, Hannah Liu, Hank Wong, Cheryl C. Saenz, Jyoti Mayadev, Michael T...> ;Journal of Nuclear Medicine. 2021 Oct 28
• 19 citations
  Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
  Neil S. Horowitz, Ramez N. Eskander, M.R. Adelman, W.M. Burke> ;Gynecologic Oncology. 2021 Oct 19
• 1 citations
  Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer
  Jessica Jou, Lindsey M. Charo, Marianne Hom-Tedla, Katherine Coakley, Pratibha Binder, Cheryl C. Saenz, Ramez N. Eskander, Michael T. McHale, Steven C. Plaxe> ;Gynecologic Oncology. 2021 Nov 1
• 15 citations
  Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.
  Casey W. Williamson, Igor Sirák, Ronghui Xu, Lorraine Portelance, Lichun Wei, Rafal Tarnawski, Umesh Mahantshetty, Elena S. Heide, Catheryn M. Yashar, Michael T. McHal...> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Aug 20
• 7 citations
  Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol.
  Zachary Berman, Marni B. Jacobs, Andrew C. Picel, Charlotte L. Conturie, Kathy Zhang-Rutledge, Pratibha Binder, Ramez N. Eskander, Anne C. Roberts, Michael T. McHale, ...> ;American Journal of Obstetrics and Gynecology. 2021 Jul 7
• 3 citations
  Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials
  Jessica Jou, Allison L. Brodsky, Lindsey M. Charo, Pratibha Binder, Cheryl C. Saenz, Ramez N. Eskander, Michael T. McHale, S.C. Plaxe> ;Gynecologic Oncology. 2021 Aug 1
• 15 citations
  Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer.
  Ryon P. Graf, Ramez N. Eskander, Leo Brueggeman, Dwayne G. Stupack> ;JAMA Network Open. 2021 Jun 1
• 1 citations
  Survey of trends in authorship assignment in gynecologic oncology: Keeping score and playing fair.
  Laura M. Chambers, Catherine H. Watson, Meng Yao, Kimberly Levinson, Ronald D. Alvarez, Ramez N. Eskander, Megan E. Buechel, Chad M. Michener, A.M. Jernigan> ;Gynecologic Oncology Reports. 2021 Mar 23
• 4 citations
  De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical ca...
  Erin E. Hahn, Corrine Munoz-Plaza, Danielle E. Altman, Chunyi Hsu, Nancy T. Cannizzaro, Quyen Ngo-Metzger, Patricia Wride, Michael K. Gould, Brian S. Mittman, Melissa ...> ;Implementation Science Communications. 2021 Sep 23
• Join now to see all

Journal Articles

• Immune Checkpoint Inhibition in the Treatment of Gynecologic Cancer  
  Kristen Anderson, Ramez N. Eskander, Current Obstetrics and Gynecology Reports, 1/14/2018
• Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)  
  Stukan, M, �Zalewski, K, �Mardas, M, D. Filarska, M Szajewski, A. Kmiec, P. Binkowska, M. Pietrzak-Stukan, M. Dudziak, J.P. Grabowski, RN Eskander, E. Greimel, European Journal of Cancer Care, 1/1/2017
• Practice Bulletin No174: Evaluation and Management of Adnexal Masses American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology  
  Eskander RN, Berman M, Keder L, Obstet Gynecol, 1/1/2016
• A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer  
  Minion LE, Bai J, Monk BJ, Robin Keller L, Ramez EN, Forde GK, Chan JK, Tewari KS, Gynecol Oncol, 1/1/2015
• Immunotherapy in endometrial cancer-an evolving therapeutic paradigm  
  Longoria TC, Eskander RN, Gynecologic Oncology Research and Practice, 1/1/2015
• Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer  
  Eskander RN, Tewari KS, Journal of Hematological Malignancies, 1/1/2012
• Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions  
  Eskander RN, Di Saia PJ, Current Angiogenesis, 1/1/2012
• Adnexal Masses in Pediatric and Adolescent Females: A review of the literature  
  Eskander RN, Bristow RE, Curr Obstet Gynecol Rep, 1/1/2011
• Join now to see all

Books/Book Chapters

• Guide to Survivorship for Women Who Have Ovarian Cancer 
  Chapter: Adding quality to life. 
  Eskander RN, Anastasia PJEditors: Bristow RE, Cornelison TL, Montz FJ.Johns Hopkins University PressEdition 2nd,2015
• Altchek's Diagnosis and Management of Ovarian Disorders 
  Chapter: Chemotherapy of ovarian cancer. 
  Page 415 - 424Eskander RN, Di Saia PJEditors: Deligdisch L, Kase NG, Cohen CJ.Cambridge University PressEdition 3rd,2013
• Textbook of Uncommon Cancer 
  Chapter: Borderline tumors and other rare epithelial tumors of the ovary. 
  Page 497 - 506Eskander RN, Diaz-Montes TP, Vang R, Armstrong DK, Bristow REEditors: Raghavan D, Blanke C, Johnson DH, Moots PL, Reaman GH, Rose PG, Sekeres MA.John Wiley & Sons, Inc.Edition 4th,2012

Abstracts/Posters

• Comprehensive genomic characterization of small cell neuroendocrine carcinoma of the cervix.
  Eskander RN, Elvin J., Charo L., et al, SGO (Society of Gynecologic Oncology) Annual Meeting, New Orleans, LA, 1/1/2018
• A phase I dose-escalation of hyperthermic intraperitoneal chemotherapy (HIPED) with carboplatin for the frontline treatment of advanced ovarian cancer (NCT02199171).
  Randall LM, Gillen D, Krill LS, Liu FW, Pfaendler K, Chen WP, Eskander RN, Tewari KS, Bristow RE, ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago, IL, 1/1/2018
• Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.
  Wolford JE, Bai J, Minion LE, Keller R, Eskander RN, Chan JK, Monk BJ, Tewari KS, ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago, IL, 1/1/2018
• ATHENA (GOG-3020/ENGOT-ov45): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of Rucaparib + Nivolumab Following Front-Line Platinum-Based Chemotherapy i...
  Bradley J. Monk, Robert L. Coleman, Keiichi Fujiwara, Amit M. Oza, Shannon N. Westin, David M. O'Malley, Thomas J. Herzog, Frederik Marme, Ana Oaknin, Ramez N. Eskande..., 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Kyoto, Japan, 1/1/2018
• Analysis of the complex immune-cell milieu of tumors from patients treated with immunotherapy to better understand clinical response.
  Shumei Kato, Ryosuke Okamura, Mina Nikanjam, Ramez Eskander, Paul Fanta, Suzanna Lee, et al, Society for Immunotherapy of Cancer, Washington, DC, 1/1/2018
• Postoperative complications and return of bowel function among patients with advanced stage ovarian cancer following rectosigmoid resection with reanastomosis.
  Sanders BE, Eskander RN, Laus K, et al, SGO (Society of Gynecologic Oncology) Annual Meeting, Washington, DC, 1/1/2017
• The impact of body mass index (BMI) classification on the likelihood of lymphadenectomy at the time of hysterectomy for endometrial cancer.
  Longoria TC, Clair KH, Paraghamian S, Vu H. Eskander RN, Bristow RE, SGO (Society of Gynecologic Oncology) Annual Meeting, Washington, DC, 1/1/2017
• Perioperative transfusion as an independent risk factor for postoperative infection in Gynecologic Oncology patients.
  Longoria TC, Alldredge J, Clair K, Randall L, Eskander RN, WAGO (Western Association of Gynecologic Oncologists) Annual Meeting, Sedona, AZ, 1/1/2016
• The predictive value of preoperative thrombocytosis for postoperative infection in ovarian cancer patients.
  Longoria TC, Alldredge J, Sawyer B, Bristow R, Eskander RN, WAGO (Western Association of Gynecologic Oncologists) Annual Meeting, Sedona, AZ, 1/1/2016
• Inhibition of the Wnt pathway in ovarian cancer tumorigenesis.
  Krill L, Jandial D, Blair C, Ji T, Eskander RN, Yokoyama N, Bristow R, Randall L, WAGO (Western Association of Gynecologic Oncologists) Annual Meeting, Sedona, AZ, 1/1/2016
• Overexpression of enhancer of zeste homolog 2 (EZH2) in endometrial carcinoma: evidence from an NRG Oncology/Gynecologic Oncology Group trial.
  Krill L, Ali S, Eskander RN, et al, AACR (American Association for Cancer Research) Annual Meeting, New Orleans, LA, 1/1/2016
• Gynecologic Oncology fellow perspectives on research and career development symposia: a Gynecologic Oncology Fellows' and Allied Health Professionals' Research Network...
  Dickson EL, Lin JL, Tergas AI, Eskander RN, Mueller JJ, Holman LL, Bristow RE, Fader AN, 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/1/2014
• Short term morbidity and mortality associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent/advanced stage ovarian cancer.
  Cripe JC, Tseng J, Eskander RN, Thompson S, Fader AN, Tanner EJ, Bristow RE, 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/1/2014
• Assessment of palliative care training in gynecologic oncology: a Gynecologic Oncology Fellows Research Network Study.
  Eskander RN, Osann K, Dickson EL, Holman LL, Rauh-Hain JA, Spoozak LA, Wu E, Fader AN, Tewari KS, 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/1/2014
• Patients with microscopic residual disease experience decreased survival when time from surgery to initiation of chemotherapy exceeds 25 days: A Gynecologic Oncology G...
  Eskander RN, Java JJ, Tewari KS, Burger RA, Monk BJ, 44th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Los Angeles, CA, 1/1/2013
• Pilot study of the PARO Therapeutic Robotic demonstrates decreased pain, fatigue, and anxiety among patients with recurrent ovarian carcinoma.
  Eskander RN, Tewari KS, Osann K, Shibata T, 44th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Los Angeles, CA, 1/1/2013
• Expression Patterns of the Wnt Pathway Inhibitors Dickkopf-3 (Dkk3) and Secreted Frizzled-Related Proteins (sFRP) 1 and 4 in Endometrial Endometrioid Adenocarcinoma: A...
  Eskander RN, Ali S, Lankes H, Dellinger T, Hoang B, Ramirez N, Monk B, Walker J, Eisenhauer E, Randall L, Gynecol Oncol, 43rd Annual Meeting on Women's Cancer-Society of Gynecologic Oncology, Austin, TX, 1/1/2012
• Beta Blocker use and Ovarian Cancer Survival: A retrospective cohort study.
  Eskander R, Bessonova L, Chui C, Ward K, Anton Culver H, Harrison T, Randall L, 43th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Austin, TX, 1/1/2012
• DKK3, a secreted Wnt antagonist, suppress tumorigenic potential and lung metastasis of osteosarcoma.
  Guo Y, Rubin E, Pourmorady J, Christ S, Rooney K, Eskander R, Sakai T, Bhatia NN, Zi X, Hoang BH, 102nd AACR (American Association for Cancer Research) Annual Clinical Meeting, Orlando, FL, 1/1/2011
• Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines.
  Sakai T, Guo Y, Eskander R, Mefford J, Hopkins J, Zi X, Bhatia NN, Hoang, BH, 102nd AACR (American Association for Cancer Research) Annual Clinical Meeting, Orlando, FL, 1/1/2011
• Flavokawain B (FKB), A novel naturally occurring chalcone, exhibits robust apoptotic effects in the treatment of a uterine leiomyosarcoma cell line.
  Eskander R, Randall L, Sakai T, Guo Y, Hoang B, Zi X, 2011 Annual WAGO (Western Association of Gynecologic Oncologists) Meeting, Park City, UT, 1/1/2011
• Sonographic Findings Associated with the Diagnosis of Invasive Placentation.
  Tache V, Eskander R, Ramos G, Benirschke K, Romine L, Moore T, American Journal of Obstetrics and Gynecology, 2010 SMFM Annual Clinical Meeting, Chicago, IL, 1/1/2010
• Prenatal vs. Intraoperative Diagnosis of Placenta Accreta: Effects on Maternal Outcomes in 100 Consecutive Cases.
  Eskander R, Warshak C, Moore TR, Resnik R, American Journal of Obstetrics and Gynecology, 2009 SMFM Annual Clinical Meeting, San Diego, CA, 1/1/2009
• The Influence of Gestational age on Urgent Delivery in Patients With Placenta Accreta-Experience with 100 Consecutive Cases.
  Eskander R, Warshak C, Moore TR, Resnik R, American Journal of Obstetrics and Gynecology, 2009 SMFM Annual Clinical Meeting, San Diego, CA, 1/1/2009
• Management Experience with 82 consecutive Cases of Placenta Accreta.
  Warshak C, Eskander R, Resnik R, 2006 ACOG (American College of Obstetricians and Gynecologists) Annual Clinical Meeting, Washington, DC, 1/1/2006
• Join now to see all

Lectures

• Epigenetic Modifiers As a Therapeutic Approach in Gynecologic Cancers 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
• Implications of opportunistic salpingectomy. The state of the science. 
  1/1/2018
• Deteccion y prevencion del cancer de ovaries & Nuevos tratamientos para el cancer hereditario. 
  San Diego, CA - 1/1/2018
• Ovarian Cancer: Emerging therapeutic Paradigms. 
  Cedars Sinai Medical Center, CA - 1/1/2018
• Epigenetic modifiers as a therapeutic approach in gynecologic cancers. 
  Chicago, IL - 1/1/2018
• Management of Immune Checkpoint Inhibitor (ICPi) related toxicities: A new...but common frontier. 
  New Orleans, LA - 1/1/2018
• Pre-operative preparation & Post-operative care. 
  1/19/2017
• UCSD Division of Gynecologic Oncology-Updates in Practice. 
  1/3/2017
• Opportunistic Salpingectomy: Implications for ovarian cancer risk reduction. 
  1/1/2016
• Patient Selection and Perioperative Care. 
  1/1/2016
• Oncology Hot Topics-Care of the Patient with Ovarian Cancer 
  UC Irvine Medical Center - 1/26/2015
• Immunotherapy in Gynecologic Cancer: Intersection of the Mutanome and Genome. 
  1/1/2015
• Synthetic lethality in ovarian cancer: The novel paradigm of PARP inhibition. 
  1/1/2015
• Ovarian Cancer: Where are we now? A review of recent advances in screening, diagnosis and treatment. 
  1/1/2015
• Development and Evolution of Ovarian Cancer Therapeutics. 
  1/1/2015
• Robotic Surgery: Where are we now? 
  1/1/2015
• Correlation between surgeon's assessment of residual disease and findings on post operative pre treatment computed tomography scan in women with advanced stage ovarian... 
  Chicago, IL - 1/1/2015
• Anti-angiogenesis therapy in ovarian cancer: The alpha and the omega. 
  1/1/2014
• Obstetrical hemorrhage and cesarean hysterectomy. 
  1/1/2014
• Gynecologic Cancers: Prevention and Screening. 
  1/1/2014
• Gynecologic Cancers: Cervical Cancer Screening. 
  1/1/2014
• Hospital readmission (30-day) following surgery for advanced stage ovarian cancer: analysis of risk factors and cost using the SEER-Medicare database. 
  Tampa, FL - 1/1/2014
• ASCO (American Society of Clinical Oncology) Update 2013. 
  1/1/2013
• Negative survival impact associated with > 25 day interval from surgical cytoreduction to initiation of systemic therapy in advanced ovarian carcinoma: A Gynecologi... 
  Los Angeles, CA - 1/1/2013
• Impact of Chemotherapy Induced Neutropenia on Survival in Patients with Solid Malignancies. 
  1/1/2012
• Join now to see all

Other

• The epigenetic landscape in the treatment of gynecologic malignancies. 
  Eskander RN, ASCO Educational Book
  1/23/2018
• Expert Opinion on the PORTEC-3 clinical trial. 
  Eskander RN, Medicine Matters Oncology
  https://oncology.medicinematters.com/expert-comment/15515530
  1/1/2018